No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 338 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR The incredible value of going public November 22, 2021 FDA Oversight of E-Cigarettes Gathers Speed: A Conversation with Mitch Zeller January 5, 2022 Cancer and Climate Change: The Health Threats of Unnatural Disasters April 5, 2023 Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal... February 10, 2025 Load more HOT NEWS How to Prepare for Lung Cancer Treatment to Help With Recovery New Radiation Therapy Won’t Leave Breast Cancer Patients with Unwanted Tattoo... New study to investigate breast cancer in ethnic minority groups Berry Recipes
